TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 5, 2014

Primary Completion Date

June 18, 2015

Study Completion Date

June 18, 2015

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

S-1+leucovorin

"Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."

Trial Locations (1)

Unknown

Chang-Gung Memorial Hospital, Linkou, Linkou District

All Listed Sponsors
collaborator

Chang Gung Memorial Hospital

OTHER

lead

TTY Biopharm

INDUSTRY

NCT03517618 - TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC | Biotech Hunter | Biotech Hunter